Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
3 hedge funds and large institutions have $1.94K invested in Protagenic Therapeutics Warrant in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
200% more funds holding
Funds holding: 1 → 3 (+2)
0.58% more ownership
Funds ownership: 4.09% → 4.68% (+0.58%)
64% less capital invested
Capital invested by funds: $5.32K → $1.94K (-$3.38K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
GTS Securities
New York
|
+$489 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $1.56K | – | – | – |
|
|
GS
2
GTS Securities
New York
| $378 | +$489 | +25,200 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $1 | +$2 | +100 | New |
|
PTIXW Hedge Fund Activity: Q4 2023 in Review
3 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q4 2023, worth a combined $1.94K — down 64% from $5.32K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PTIXW positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was GTS Securities, opening a new position worth an estimated $489.
- 3 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q4 2023, up from 1 in Q3 2023.
- Funds reported $1.94K of Protagenic Therapeutics Warrant stock for Q4 2023, down 64% quarter-over-quarter.
- 2 funds opened new Protagenic Therapeutics Warrant positions in Q4 2023 and 0 closed out, a net change of +2 holders.
- The largest Protagenic Therapeutics Warrant buyer in Q4 2023 was GTS Securities, an estimated $489 added.
Based on aggregated 13F filings for Q4 2023.